nodes	percent_of_prediction	percent_of_DWPC	metapath
Maprotiline—Dimetacrine—Tamoxifen—pancreatic cancer	0.309	1	CrCrCtD
Maprotiline—ORM1—Erlotinib—pancreatic cancer	0.0912	0.251	CbGbCtD
Maprotiline—CYP1A2—Dacarbazine—pancreatic cancer	0.0339	0.0932	CbGbCtD
Maprotiline—CYP1A2—Tamoxifen—pancreatic cancer	0.027	0.0742	CbGbCtD
Maprotiline—ABCB1—Tamoxifen—pancreatic cancer	0.0236	0.0648	CbGbCtD
Maprotiline—CYP1A2—Erlotinib—pancreatic cancer	0.0229	0.0631	CbGbCtD
Maprotiline—CYP2D6—Tamoxifen—pancreatic cancer	0.0222	0.0611	CbGbCtD
Maprotiline—ABCB1—Gemcitabine—pancreatic cancer	0.0203	0.0559	CbGbCtD
Maprotiline—ABCB1—Erlotinib—pancreatic cancer	0.0201	0.0551	CbGbCtD
Maprotiline—CYP1A2—Fluorouracil—pancreatic cancer	0.0199	0.0546	CbGbCtD
Maprotiline—CYP2D6—Erlotinib—pancreatic cancer	0.0189	0.052	CbGbCtD
Maprotiline—ABCB1—Irinotecan—pancreatic cancer	0.0181	0.0498	CbGbCtD
Maprotiline—ABCB1—Docetaxel—pancreatic cancer	0.0133	0.0365	CbGbCtD
Maprotiline—ABCB1—Sunitinib—pancreatic cancer	0.0132	0.0363	CbGbCtD
Maprotiline—HTR7—enteric nervous system—pancreatic cancer	0.00995	0.343	CbGeAlD
Maprotiline—ABCB1—Doxorubicin—pancreatic cancer	0.0099	0.0272	CbGbCtD
Maprotiline—CYP2D6—Doxorubicin—pancreatic cancer	0.00933	0.0256	CbGbCtD
Maprotiline—ORM1—bile—pancreatic cancer	0.00723	0.249	CbGeAlD
Maprotiline—HTR2A—enteric nervous system—pancreatic cancer	0.0062	0.214	CbGeAlD
Maprotiline—ORM1—gall bladder—pancreatic cancer	0.00201	0.0691	CbGeAlD
Maprotiline—CHRM3—digestive system—pancreatic cancer	0.0006	0.0207	CbGeAlD
Maprotiline—HTR7—digestive system—pancreatic cancer	0.000571	0.0197	CbGeAlD
Maprotiline—CYP1A2—digestive system—pancreatic cancer	0.000455	0.0157	CbGeAlD
Maprotiline—HRH1—digestive system—pancreatic cancer	0.000426	0.0147	CbGeAlD
Maprotiline—ABCB1—islet of Langerhans—pancreatic cancer	0.000388	0.0134	CbGeAlD
Maprotiline—HTR2A—digestive system—pancreatic cancer	0.000356	0.0123	CbGeAlD
Maprotiline—CYP2D6—digestive system—pancreatic cancer	0.000324	0.0112	CbGeAlD
Maprotiline—ABCB1—pancreas—pancreatic cancer	0.000273	0.00941	CbGeAlD
Maprotiline—ABCB1—digestive system—pancreatic cancer	0.000233	0.00804	CbGeAlD
Maprotiline—Paraesthesia—Fluorouracil—pancreatic cancer	0.000211	0.00117	CcSEcCtD
Maprotiline—Alopecia—Docetaxel—pancreatic cancer	0.00021	0.00117	CcSEcCtD
Maprotiline—Pruritus—Sunitinib—pancreatic cancer	0.00021	0.00117	CcSEcCtD
Maprotiline—Breast disorder—Epirubicin—pancreatic cancer	0.00021	0.00117	CcSEcCtD
Maprotiline—Constipation—Irinotecan—pancreatic cancer	0.000209	0.00117	CcSEcCtD
Maprotiline—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	0.000209	0.00117	CcSEcCtD
Maprotiline—Somnolence—Fluorouracil—pancreatic cancer	0.000208	0.00116	CcSEcCtD
Maprotiline—Malnutrition—Docetaxel—pancreatic cancer	0.000207	0.00116	CcSEcCtD
Maprotiline—Dyspepsia—Fluorouracil—pancreatic cancer	0.000206	0.00115	CcSEcCtD
Maprotiline—Nausea—Tamoxifen—pancreatic cancer	0.000206	0.00115	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000206	0.00115	CcSEcCtD
Maprotiline—Fatigue—Gemcitabine—pancreatic cancer	0.000206	0.00115	CcSEcCtD
Maprotiline—Muscular weakness—Epirubicin—pancreatic cancer	0.000205	0.00114	CcSEcCtD
Maprotiline—Constipation—Gemcitabine—pancreatic cancer	0.000204	0.00114	CcSEcCtD
Maprotiline—Nausea—Erlotinib—pancreatic cancer	0.000204	0.00114	CcSEcCtD
Maprotiline—Diarrhoea—Sunitinib—pancreatic cancer	0.000203	0.00113	CcSEcCtD
Maprotiline—Dysgeusia—Docetaxel—pancreatic cancer	0.000203	0.00113	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000202	0.00113	CcSEcCtD
Maprotiline—Ataxia—Doxorubicin—pancreatic cancer	0.000202	0.00113	CcSEcCtD
Maprotiline—Feeling abnormal—Irinotecan—pancreatic cancer	0.000202	0.00112	CcSEcCtD
Maprotiline—Dysphagia—Epirubicin—pancreatic cancer	0.000201	0.00112	CcSEcCtD
Maprotiline—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.0002	0.00112	CcSEcCtD
Maprotiline—Eosinophilia—Epirubicin—pancreatic cancer	0.000199	0.00111	CcSEcCtD
Maprotiline—Liver function test abnormal—Doxorubicin—pancreatic cancer	0.000198	0.00111	CcSEcCtD
Maprotiline—Dizziness—Sunitinib—pancreatic cancer	0.000196	0.00109	CcSEcCtD
Maprotiline—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000196	0.00109	CcSEcCtD
Maprotiline—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000196	0.00109	CcSEcCtD
Maprotiline—Breast disorder—Doxorubicin—pancreatic cancer	0.000194	0.00108	CcSEcCtD
Maprotiline—Abdominal pain—Irinotecan—pancreatic cancer	0.000193	0.00108	CcSEcCtD
Maprotiline—Body temperature increased—Irinotecan—pancreatic cancer	0.000193	0.00108	CcSEcCtD
Maprotiline—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	0.000193	0.00108	CcSEcCtD
Maprotiline—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000193	0.00108	CcSEcCtD
Maprotiline—Pancytopenia—Epirubicin—pancreatic cancer	0.000191	0.00106	CcSEcCtD
Maprotiline—Muscular weakness—Doxorubicin—pancreatic cancer	0.000189	0.00106	CcSEcCtD
Maprotiline—Vomiting—Sunitinib—pancreatic cancer	0.000189	0.00105	CcSEcCtD
Maprotiline—Body temperature increased—Gemcitabine—pancreatic cancer	0.000188	0.00105	CcSEcCtD
Maprotiline—Rash—Sunitinib—pancreatic cancer	0.000187	0.00104	CcSEcCtD
Maprotiline—Dermatitis—Sunitinib—pancreatic cancer	0.000187	0.00104	CcSEcCtD
Maprotiline—Urticaria—Fluorouracil—pancreatic cancer	0.000186	0.00104	CcSEcCtD
Maprotiline—Headache—Sunitinib—pancreatic cancer	0.000186	0.00104	CcSEcCtD
Maprotiline—Syncope—Docetaxel—pancreatic cancer	0.000186	0.00104	CcSEcCtD
Maprotiline—Dysphagia—Doxorubicin—pancreatic cancer	0.000186	0.00103	CcSEcCtD
Maprotiline—Leukopenia—Docetaxel—pancreatic cancer	0.000186	0.00103	CcSEcCtD
Maprotiline—Pollakiuria—Epirubicin—pancreatic cancer	0.000185	0.00103	CcSEcCtD
Maprotiline—Body temperature increased—Fluorouracil—pancreatic cancer	0.000185	0.00103	CcSEcCtD
Maprotiline—Eosinophilia—Doxorubicin—pancreatic cancer	0.000184	0.00102	CcSEcCtD
Maprotiline—Palpitations—Docetaxel—pancreatic cancer	0.000183	0.00102	CcSEcCtD
Maprotiline—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.000183	0.00102	CcSEcCtD
Maprotiline—Weight increased—Epirubicin—pancreatic cancer	0.000183	0.00102	CcSEcCtD
Maprotiline—Loss of consciousness—Docetaxel—pancreatic cancer	0.000182	0.00102	CcSEcCtD
Maprotiline—Weight decreased—Epirubicin—pancreatic cancer	0.000182	0.00101	CcSEcCtD
Maprotiline—Convulsion—Docetaxel—pancreatic cancer	0.00018	0.001	CcSEcCtD
Maprotiline—Hypertension—Docetaxel—pancreatic cancer	0.000179	0.000997	CcSEcCtD
Maprotiline—Infestation NOS—Epirubicin—pancreatic cancer	0.000179	0.000997	CcSEcCtD
Maprotiline—Infestation—Epirubicin—pancreatic cancer	0.000179	0.000997	CcSEcCtD
Maprotiline—Drowsiness—Epirubicin—pancreatic cancer	0.000179	0.000997	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.000177	0.000989	CcSEcCtD
Maprotiline—Nausea—Sunitinib—pancreatic cancer	0.000176	0.000983	CcSEcCtD
Maprotiline—Pancytopenia—Doxorubicin—pancreatic cancer	0.000176	0.000983	CcSEcCtD
Maprotiline—Asthenia—Irinotecan—pancreatic cancer	0.000176	0.000979	CcSEcCtD
Maprotiline—Neuropathy peripheral—Epirubicin—pancreatic cancer	0.000175	0.000977	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000175	0.000977	CcSEcCtD
Maprotiline—Stomatitis—Epirubicin—pancreatic cancer	0.000174	0.000972	CcSEcCtD
Maprotiline—Jaundice—Epirubicin—pancreatic cancer	0.000174	0.000972	CcSEcCtD
Maprotiline—Dry mouth—Docetaxel—pancreatic cancer	0.000173	0.000962	CcSEcCtD
Maprotiline—Pollakiuria—Doxorubicin—pancreatic cancer	0.000172	0.000956	CcSEcCtD
Maprotiline—Asthenia—Gemcitabine—pancreatic cancer	0.000171	0.000953	CcSEcCtD
Maprotiline—Confusional state—Docetaxel—pancreatic cancer	0.000171	0.000951	CcSEcCtD
Maprotiline—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000169	0.000944	CcSEcCtD
Maprotiline—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000169	0.000943	CcSEcCtD
Maprotiline—Oedema—Docetaxel—pancreatic cancer	0.000169	0.000943	CcSEcCtD
Maprotiline—Weight increased—Doxorubicin—pancreatic cancer	0.000169	0.000942	CcSEcCtD
Maprotiline—Pruritus—Gemcitabine—pancreatic cancer	0.000169	0.00094	CcSEcCtD
Maprotiline—Infection—Docetaxel—pancreatic cancer	0.000168	0.000937	CcSEcCtD
Maprotiline—Weight decreased—Doxorubicin—pancreatic cancer	0.000168	0.000936	CcSEcCtD
Maprotiline—Diarrhoea—Irinotecan—pancreatic cancer	0.000167	0.000933	CcSEcCtD
Maprotiline—Agranulocytosis—Epirubicin—pancreatic cancer	0.000167	0.00093	CcSEcCtD
Maprotiline—Shock—Docetaxel—pancreatic cancer	0.000166	0.000928	CcSEcCtD
Maprotiline—Nervous system disorder—Docetaxel—pancreatic cancer	0.000166	0.000925	CcSEcCtD
Maprotiline—Pruritus—Fluorouracil—pancreatic cancer	0.000166	0.000924	CcSEcCtD
Maprotiline—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000166	0.000923	CcSEcCtD
Maprotiline—Infestation NOS—Doxorubicin—pancreatic cancer	0.000166	0.000923	CcSEcCtD
Maprotiline—Drowsiness—Doxorubicin—pancreatic cancer	0.000166	0.000923	CcSEcCtD
Maprotiline—Infestation—Doxorubicin—pancreatic cancer	0.000166	0.000923	CcSEcCtD
Maprotiline—Tachycardia—Docetaxel—pancreatic cancer	0.000165	0.00092	CcSEcCtD
Maprotiline—Skin disorder—Docetaxel—pancreatic cancer	0.000164	0.000916	CcSEcCtD
Maprotiline—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.000164	0.000915	CcSEcCtD
Maprotiline—Diarrhoea—Gemcitabine—pancreatic cancer	0.000163	0.000909	CcSEcCtD
Maprotiline—Neuropathy peripheral—Doxorubicin—pancreatic cancer	0.000162	0.000904	CcSEcCtD
Maprotiline—Dizziness—Irinotecan—pancreatic cancer	0.000162	0.000902	CcSEcCtD
Maprotiline—Stomatitis—Doxorubicin—pancreatic cancer	0.000161	0.000899	CcSEcCtD
Maprotiline—Jaundice—Doxorubicin—pancreatic cancer	0.000161	0.000899	CcSEcCtD
Maprotiline—Hepatitis—Epirubicin—pancreatic cancer	0.000161	0.000895	CcSEcCtD
Maprotiline—Diarrhoea—Fluorouracil—pancreatic cancer	0.00016	0.000894	CcSEcCtD
Maprotiline—Hypoaesthesia—Epirubicin—pancreatic cancer	0.00016	0.000891	CcSEcCtD
Maprotiline—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000159	0.000884	CcSEcCtD
Maprotiline—Hypotension—Docetaxel—pancreatic cancer	0.000158	0.000881	CcSEcCtD
Maprotiline—Urethral disorder—Epirubicin—pancreatic cancer	0.000157	0.000877	CcSEcCtD
Maprotiline—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000157	0.000873	CcSEcCtD
Maprotiline—Vomiting—Irinotecan—pancreatic cancer	0.000156	0.000867	CcSEcCtD
Maprotiline—Dizziness—Fluorouracil—pancreatic cancer	0.000155	0.000864	CcSEcCtD
Maprotiline—Agranulocytosis—Doxorubicin—pancreatic cancer	0.000155	0.000861	CcSEcCtD
Maprotiline—Rash—Irinotecan—pancreatic cancer	0.000154	0.00086	CcSEcCtD
Maprotiline—Dermatitis—Irinotecan—pancreatic cancer	0.000154	0.000859	CcSEcCtD
Maprotiline—Headache—Irinotecan—pancreatic cancer	0.000153	0.000854	CcSEcCtD
Maprotiline—Insomnia—Docetaxel—pancreatic cancer	0.000153	0.000853	CcSEcCtD
Maprotiline—Paraesthesia—Docetaxel—pancreatic cancer	0.000152	0.000847	CcSEcCtD
Maprotiline—Erythema multiforme—Epirubicin—pancreatic cancer	0.000152	0.000846	CcSEcCtD
Maprotiline—Vomiting—Gemcitabine—pancreatic cancer	0.000152	0.000845	CcSEcCtD
Maprotiline—Somnolence—Docetaxel—pancreatic cancer	0.00015	0.000838	CcSEcCtD
Maprotiline—Rash—Gemcitabine—pancreatic cancer	0.00015	0.000838	CcSEcCtD
Maprotiline—Dermatitis—Gemcitabine—pancreatic cancer	0.00015	0.000837	CcSEcCtD
Maprotiline—Eye disorder—Epirubicin—pancreatic cancer	0.00015	0.000836	CcSEcCtD
Maprotiline—Tinnitus—Epirubicin—pancreatic cancer	0.00015	0.000835	CcSEcCtD
Maprotiline—Headache—Gemcitabine—pancreatic cancer	0.000149	0.000832	CcSEcCtD
Maprotiline—Flushing—Epirubicin—pancreatic cancer	0.000149	0.000831	CcSEcCtD
Maprotiline—Cardiac disorder—Epirubicin—pancreatic cancer	0.000149	0.000831	CcSEcCtD
Maprotiline—Vomiting—Fluorouracil—pancreatic cancer	0.000149	0.000831	CcSEcCtD
Maprotiline—Dyspepsia—Docetaxel—pancreatic cancer	0.000149	0.00083	CcSEcCtD
Maprotiline—Hepatitis—Doxorubicin—pancreatic cancer	0.000149	0.000828	CcSEcCtD
Maprotiline—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000148	0.000824	CcSEcCtD
Maprotiline—Rash—Fluorouracil—pancreatic cancer	0.000148	0.000824	CcSEcCtD
Maprotiline—Dermatitis—Fluorouracil—pancreatic cancer	0.000148	0.000823	CcSEcCtD
Maprotiline—Headache—Fluorouracil—pancreatic cancer	0.000147	0.000818	CcSEcCtD
Maprotiline—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000147	0.000818	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000146	0.000814	CcSEcCtD
Maprotiline—Fatigue—Docetaxel—pancreatic cancer	0.000146	0.000813	CcSEcCtD
Maprotiline—Angiopathy—Epirubicin—pancreatic cancer	0.000146	0.000812	CcSEcCtD
Maprotiline—Urethral disorder—Doxorubicin—pancreatic cancer	0.000146	0.000812	CcSEcCtD
Maprotiline—Nausea—Irinotecan—pancreatic cancer	0.000145	0.00081	CcSEcCtD
Maprotiline—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000145	0.000807	CcSEcCtD
Maprotiline—Constipation—Docetaxel—pancreatic cancer	0.000145	0.000806	CcSEcCtD
Maprotiline—Arrhythmia—Epirubicin—pancreatic cancer	0.000144	0.0008	CcSEcCtD
Maprotiline—Alopecia—Epirubicin—pancreatic cancer	0.000142	0.000791	CcSEcCtD
Maprotiline—Nausea—Gemcitabine—pancreatic cancer	0.000142	0.000789	CcSEcCtD
Maprotiline—Erythema multiforme—Doxorubicin—pancreatic cancer	0.000141	0.000783	CcSEcCtD
Maprotiline—Malnutrition—Epirubicin—pancreatic cancer	0.00014	0.000779	CcSEcCtD
Maprotiline—Feeling abnormal—Docetaxel—pancreatic cancer	0.000139	0.000777	CcSEcCtD
Maprotiline—Nausea—Fluorouracil—pancreatic cancer	0.000139	0.000776	CcSEcCtD
Maprotiline—Eye disorder—Doxorubicin—pancreatic cancer	0.000139	0.000774	CcSEcCtD
Maprotiline—Tinnitus—Doxorubicin—pancreatic cancer	0.000139	0.000772	CcSEcCtD
Maprotiline—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000138	0.000771	CcSEcCtD
Maprotiline—Flushing—Doxorubicin—pancreatic cancer	0.000138	0.000769	CcSEcCtD
Maprotiline—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000138	0.000769	CcSEcCtD
Maprotiline—Tension—Epirubicin—pancreatic cancer	0.000137	0.000765	CcSEcCtD
Maprotiline—Dysgeusia—Epirubicin—pancreatic cancer	0.000137	0.000763	CcSEcCtD
Maprotiline—Nervousness—Epirubicin—pancreatic cancer	0.000136	0.000757	CcSEcCtD
Maprotiline—Angiopathy—Doxorubicin—pancreatic cancer	0.000135	0.000751	CcSEcCtD
Maprotiline—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000134	0.000746	CcSEcCtD
Maprotiline—Abdominal pain—Docetaxel—pancreatic cancer	0.000134	0.000745	CcSEcCtD
Maprotiline—Body temperature increased—Docetaxel—pancreatic cancer	0.000134	0.000745	CcSEcCtD
Maprotiline—Arrhythmia—Doxorubicin—pancreatic cancer	0.000133	0.00074	CcSEcCtD
Maprotiline—Vision blurred—Epirubicin—pancreatic cancer	0.000132	0.000734	CcSEcCtD
Maprotiline—Alopecia—Doxorubicin—pancreatic cancer	0.000131	0.000732	CcSEcCtD
Maprotiline—Malnutrition—Doxorubicin—pancreatic cancer	0.000129	0.000721	CcSEcCtD
Maprotiline—Agitation—Epirubicin—pancreatic cancer	0.000129	0.000716	CcSEcCtD
Maprotiline—Tension—Doxorubicin—pancreatic cancer	0.000127	0.000707	CcSEcCtD
Maprotiline—Dysgeusia—Doxorubicin—pancreatic cancer	0.000127	0.000706	CcSEcCtD
Maprotiline—Nervousness—Doxorubicin—pancreatic cancer	0.000126	0.0007	CcSEcCtD
Maprotiline—Syncope—Epirubicin—pancreatic cancer	0.000125	0.000699	CcSEcCtD
Maprotiline—Leukopenia—Epirubicin—pancreatic cancer	0.000125	0.000697	CcSEcCtD
Maprotiline—Palpitations—Epirubicin—pancreatic cancer	0.000124	0.000689	CcSEcCtD
Maprotiline—Loss of consciousness—Epirubicin—pancreatic cancer	0.000123	0.000685	CcSEcCtD
Maprotiline—Vision blurred—Doxorubicin—pancreatic cancer	0.000122	0.000679	CcSEcCtD
Maprotiline—Asthenia—Docetaxel—pancreatic cancer	0.000121	0.000676	CcSEcCtD
Maprotiline—Convulsion—Epirubicin—pancreatic cancer	0.000121	0.000675	CcSEcCtD
Maprotiline—Hypertension—Epirubicin—pancreatic cancer	0.000121	0.000673	CcSEcCtD
Maprotiline—Pruritus—Docetaxel—pancreatic cancer	0.00012	0.000667	CcSEcCtD
Maprotiline—Agitation—Doxorubicin—pancreatic cancer	0.000119	0.000663	CcSEcCtD
Maprotiline—Anxiety—Epirubicin—pancreatic cancer	0.000119	0.000661	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000118	0.000659	CcSEcCtD
Maprotiline—Dry mouth—Epirubicin—pancreatic cancer	0.000116	0.000649	CcSEcCtD
Maprotiline—Syncope—Doxorubicin—pancreatic cancer	0.000116	0.000647	CcSEcCtD
Maprotiline—Leukopenia—Doxorubicin—pancreatic cancer	0.000116	0.000645	CcSEcCtD
Maprotiline—Diarrhoea—Docetaxel—pancreatic cancer	0.000116	0.000645	CcSEcCtD
Maprotiline—Confusional state—Epirubicin—pancreatic cancer	0.000115	0.000641	CcSEcCtD
Maprotiline—Palpitations—Doxorubicin—pancreatic cancer	0.000114	0.000637	CcSEcCtD
Maprotiline—Oedema—Epirubicin—pancreatic cancer	0.000114	0.000636	CcSEcCtD
Maprotiline—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000114	0.000634	CcSEcCtD
Maprotiline—Infection—Epirubicin—pancreatic cancer	0.000113	0.000632	CcSEcCtD
Maprotiline—Shock—Epirubicin—pancreatic cancer	0.000112	0.000626	CcSEcCtD
Maprotiline—Convulsion—Doxorubicin—pancreatic cancer	0.000112	0.000625	CcSEcCtD
Maprotiline—Nervous system disorder—Epirubicin—pancreatic cancer	0.000112	0.000624	CcSEcCtD
Maprotiline—Dizziness—Docetaxel—pancreatic cancer	0.000112	0.000623	CcSEcCtD
Maprotiline—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000112	0.000623	CcSEcCtD
Maprotiline—Hypertension—Doxorubicin—pancreatic cancer	0.000112	0.000622	CcSEcCtD
Maprotiline—Tachycardia—Epirubicin—pancreatic cancer	0.000111	0.000621	CcSEcCtD
Maprotiline—Skin disorder—Epirubicin—pancreatic cancer	0.000111	0.000618	CcSEcCtD
Maprotiline—Hyperhidrosis—Epirubicin—pancreatic cancer	0.00011	0.000615	CcSEcCtD
Maprotiline—Anxiety—Doxorubicin—pancreatic cancer	0.00011	0.000612	CcSEcCtD
Maprotiline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000109	0.00061	CcSEcCtD
Maprotiline—Dry mouth—Doxorubicin—pancreatic cancer	0.000108	0.0006	CcSEcCtD
Maprotiline—Vomiting—Docetaxel—pancreatic cancer	0.000108	0.000599	CcSEcCtD
Maprotiline—Rash—Docetaxel—pancreatic cancer	0.000107	0.000594	CcSEcCtD
Maprotiline—Hypotension—Epirubicin—pancreatic cancer	0.000107	0.000594	CcSEcCtD
Maprotiline—Dermatitis—Docetaxel—pancreatic cancer	0.000107	0.000594	CcSEcCtD
Maprotiline—Confusional state—Doxorubicin—pancreatic cancer	0.000106	0.000593	CcSEcCtD
Maprotiline—Headache—Docetaxel—pancreatic cancer	0.000106	0.000591	CcSEcCtD
Maprotiline—Oedema—Doxorubicin—pancreatic cancer	0.000106	0.000588	CcSEcCtD
Maprotiline—Infection—Doxorubicin—pancreatic cancer	0.000105	0.000585	CcSEcCtD
Maprotiline—Shock—Doxorubicin—pancreatic cancer	0.000104	0.000579	CcSEcCtD
Maprotiline—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000104	0.000577	CcSEcCtD
Maprotiline—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000103	0.000576	CcSEcCtD
Maprotiline—Insomnia—Epirubicin—pancreatic cancer	0.000103	0.000575	CcSEcCtD
Maprotiline—Tachycardia—Doxorubicin—pancreatic cancer	0.000103	0.000574	CcSEcCtD
Maprotiline—Skin disorder—Doxorubicin—pancreatic cancer	0.000103	0.000572	CcSEcCtD
Maprotiline—Paraesthesia—Epirubicin—pancreatic cancer	0.000102	0.000571	CcSEcCtD
Maprotiline—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000102	0.000569	CcSEcCtD
Maprotiline—Somnolence—Epirubicin—pancreatic cancer	0.000101	0.000565	CcSEcCtD
Maprotiline—Nausea—Docetaxel—pancreatic cancer	0.000101	0.00056	CcSEcCtD
Maprotiline—Dyspepsia—Epirubicin—pancreatic cancer	0.0001	0.00056	CcSEcCtD
Maprotiline—Hypotension—Doxorubicin—pancreatic cancer	9.87e-05	0.00055	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Epirubicin—pancreatic cancer	9.85e-05	0.000549	CcSEcCtD
Maprotiline—Fatigue—Epirubicin—pancreatic cancer	9.84e-05	0.000548	CcSEcCtD
Maprotiline—Constipation—Epirubicin—pancreatic cancer	9.76e-05	0.000544	CcSEcCtD
Maprotiline—Insomnia—Doxorubicin—pancreatic cancer	9.55e-05	0.000532	CcSEcCtD
Maprotiline—Paraesthesia—Doxorubicin—pancreatic cancer	9.48e-05	0.000528	CcSEcCtD
Maprotiline—Feeling abnormal—Epirubicin—pancreatic cancer	9.4e-05	0.000524	CcSEcCtD
Maprotiline—Somnolence—Doxorubicin—pancreatic cancer	9.39e-05	0.000523	CcSEcCtD
Maprotiline—Gastrointestinal pain—Epirubicin—pancreatic cancer	9.33e-05	0.00052	CcSEcCtD
Maprotiline—Dyspepsia—Doxorubicin—pancreatic cancer	9.3e-05	0.000518	CcSEcCtD
Maprotiline—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	9.12e-05	0.000508	CcSEcCtD
Maprotiline—Fatigue—Doxorubicin—pancreatic cancer	9.1e-05	0.000507	CcSEcCtD
Maprotiline—Urticaria—Epirubicin—pancreatic cancer	9.07e-05	0.000505	CcSEcCtD
Maprotiline—Constipation—Doxorubicin—pancreatic cancer	9.03e-05	0.000503	CcSEcCtD
Maprotiline—Body temperature increased—Epirubicin—pancreatic cancer	9.02e-05	0.000503	CcSEcCtD
Maprotiline—Abdominal pain—Epirubicin—pancreatic cancer	9.02e-05	0.000503	CcSEcCtD
Maprotiline—Feeling abnormal—Doxorubicin—pancreatic cancer	8.7e-05	0.000485	CcSEcCtD
Maprotiline—Gastrointestinal pain—Doxorubicin—pancreatic cancer	8.63e-05	0.000481	CcSEcCtD
Maprotiline—Urticaria—Doxorubicin—pancreatic cancer	8.39e-05	0.000467	CcSEcCtD
Maprotiline—Abdominal pain—Doxorubicin—pancreatic cancer	8.35e-05	0.000465	CcSEcCtD
Maprotiline—Body temperature increased—Doxorubicin—pancreatic cancer	8.35e-05	0.000465	CcSEcCtD
Maprotiline—Asthenia—Epirubicin—pancreatic cancer	8.19e-05	0.000456	CcSEcCtD
Maprotiline—Pruritus—Epirubicin—pancreatic cancer	8.07e-05	0.00045	CcSEcCtD
Maprotiline—Diarrhoea—Epirubicin—pancreatic cancer	7.81e-05	0.000435	CcSEcCtD
Maprotiline—Asthenia—Doxorubicin—pancreatic cancer	7.58e-05	0.000422	CcSEcCtD
Maprotiline—Dizziness—Epirubicin—pancreatic cancer	7.55e-05	0.000421	CcSEcCtD
Maprotiline—Pruritus—Doxorubicin—pancreatic cancer	7.47e-05	0.000416	CcSEcCtD
Maprotiline—Vomiting—Epirubicin—pancreatic cancer	7.26e-05	0.000404	CcSEcCtD
Maprotiline—Diarrhoea—Doxorubicin—pancreatic cancer	7.23e-05	0.000403	CcSEcCtD
Maprotiline—Rash—Epirubicin—pancreatic cancer	7.2e-05	0.000401	CcSEcCtD
Maprotiline—Dermatitis—Epirubicin—pancreatic cancer	7.19e-05	0.000401	CcSEcCtD
Maprotiline—Headache—Epirubicin—pancreatic cancer	7.15e-05	0.000398	CcSEcCtD
Maprotiline—Dizziness—Doxorubicin—pancreatic cancer	6.98e-05	0.000389	CcSEcCtD
Maprotiline—Nausea—Epirubicin—pancreatic cancer	6.78e-05	0.000378	CcSEcCtD
Maprotiline—Vomiting—Doxorubicin—pancreatic cancer	6.71e-05	0.000374	CcSEcCtD
Maprotiline—Rash—Doxorubicin—pancreatic cancer	6.66e-05	0.000371	CcSEcCtD
Maprotiline—Dermatitis—Doxorubicin—pancreatic cancer	6.65e-05	0.000371	CcSEcCtD
Maprotiline—Headache—Doxorubicin—pancreatic cancer	6.62e-05	0.000369	CcSEcCtD
Maprotiline—Nausea—Doxorubicin—pancreatic cancer	6.27e-05	0.00035	CcSEcCtD
Maprotiline—HTR2C—Signaling by GPCR—PIK3CA—pancreatic cancer	7.16e-06	6.04e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—EGFR—pancreatic cancer	7.15e-06	6.03e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PIK3CB—pancreatic cancer	7.15e-06	6.03e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—EGFR—pancreatic cancer	7.13e-06	6.01e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—SRC—pancreatic cancer	7.12e-06	6.01e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—EGFR—pancreatic cancer	7.1e-06	6e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PTGS2—pancreatic cancer	7.08e-06	5.98e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—EGFR—pancreatic cancer	7.03e-06	5.94e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PIK3CD—pancreatic cancer	7.03e-06	5.93e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	7.02e-06	5.93e-05	CbGpPWpGaD
Maprotiline—DRD2—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.96e-06	5.87e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—PIK3CB—pancreatic cancer	6.94e-06	5.86e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—VEGFA—pancreatic cancer	6.94e-06	5.86e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PIK3CD—pancreatic cancer	6.91e-06	5.84e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PIK3CD—pancreatic cancer	6.9e-06	5.82e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—KRAS—pancreatic cancer	6.88e-06	5.81e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PIK3CD—pancreatic cancer	6.88e-06	5.8e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—STAT3—pancreatic cancer	6.87e-06	5.8e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PIK3CD—pancreatic cancer	6.85e-06	5.79e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—NRAS—pancreatic cancer	6.85e-06	5.78e-05	CbGpPWpGaD
Maprotiline—HTR2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.85e-06	5.78e-05	CbGpPWpGaD
Maprotiline—HRH1—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.83e-06	5.77e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—SRC—pancreatic cancer	6.82e-06	5.76e-05	CbGpPWpGaD
Maprotiline—CHRM1—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.81e-06	5.75e-05	CbGpPWpGaD
Maprotiline—CHRM3—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.79e-06	5.73e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PIK3CD—pancreatic cancer	6.79e-06	5.73e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—KRAS—pancreatic cancer	6.77e-06	5.71e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—MYC—pancreatic cancer	6.76e-06	5.71e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—KRAS—pancreatic cancer	6.75e-06	5.7e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—TGFB1—pancreatic cancer	6.74e-06	5.69e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—KRAS—pancreatic cancer	6.73e-06	5.68e-05	CbGpPWpGaD
Maprotiline—CHRM2—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.72e-06	5.67e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—KRAS—pancreatic cancer	6.71e-06	5.66e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CXCL8—pancreatic cancer	6.67e-06	5.63e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—KRAS—pancreatic cancer	6.65e-06	5.61e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—VEGFA—pancreatic cancer	6.64e-06	5.61e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—HRAS—pancreatic cancer	6.63e-06	5.59e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—EGFR—pancreatic cancer	6.61e-06	5.58e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—STAT3—pancreatic cancer	6.58e-06	5.55e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—NRAS—pancreatic cancer	6.56e-06	5.54e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—APOE—pancreatic cancer	6.56e-06	5.53e-05	CbGpPWpGaD
Maprotiline—HTR2C—GPCR downstream signaling—AKT1—pancreatic cancer	6.44e-06	5.44e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—TYMS—pancreatic cancer	6.44e-06	5.43e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—MYC—pancreatic cancer	6.38e-06	5.39e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CASP3—pancreatic cancer	6.38e-06	5.39e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—TGFB1—pancreatic cancer	6.37e-06	5.37e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—PIK3CA—pancreatic cancer	6.32e-06	5.33e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—KRAS—pancreatic cancer	6.25e-06	5.27e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—EGFR—pancreatic cancer	6.24e-06	5.27e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—PIK3CA—pancreatic cancer	6.22e-06	5.25e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CCND1—pancreatic cancer	6.21e-06	5.24e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—PIK3CA—pancreatic cancer	6.2e-06	5.24e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—PIK3CA—pancreatic cancer	6.19e-06	5.22e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—APOE—pancreatic cancer	6.18e-06	5.21e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PTEN—pancreatic cancer	6.17e-06	5.21e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—PIK3CA—pancreatic cancer	6.17e-06	5.2e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—CTNNB1—pancreatic cancer	6.15e-06	5.19e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PIK3CB—pancreatic cancer	6.12e-06	5.17e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—MYC—pancreatic cancer	6.11e-06	5.16e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—PIK3CA—pancreatic cancer	6.11e-06	5.15e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TGFB1—pancreatic cancer	6.1e-06	5.15e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MMP9—pancreatic cancer	6.03e-06	5.09e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PIK3CB—pancreatic cancer	6.03e-06	5.09e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PIK3CB—pancreatic cancer	6.01e-06	5.08e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—PTEN—pancreatic cancer	6e-06	5.06e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PIK3CB—pancreatic cancer	5.99e-06	5.06e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—EGFR—pancreatic cancer	5.98e-06	5.05e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PIK3CB—pancreatic cancer	5.97e-06	5.04e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CG—pancreatic cancer	5.92e-06	4.99e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PIK3CB—pancreatic cancer	5.92e-06	4.99e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—KRAS—pancreatic cancer	5.9e-06	4.98e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CXCL8—pancreatic cancer	5.89e-06	4.97e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	5.85e-06	4.94e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—HRAS—pancreatic cancer	5.85e-06	4.94e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	5.79e-06	4.89e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CXCL8—pancreatic cancer	5.78e-06	4.88e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CXCL8—pancreatic cancer	5.76e-06	4.86e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	5.75e-06	4.86e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CXCL8—pancreatic cancer	5.74e-06	4.85e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—HRAS—pancreatic cancer	5.74e-06	4.85e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—PIK3CA—pancreatic cancer	5.74e-06	4.84e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—HRAS—pancreatic cancer	5.72e-06	4.83e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PPARG—pancreatic cancer	5.71e-06	4.82e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—HRAS—pancreatic cancer	5.7e-06	4.81e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CXCL8—pancreatic cancer	5.69e-06	4.8e-05	CbGpPWpGaD
Maprotiline—DRD2—GPCR downstream signaling—AKT1—pancreatic cancer	5.69e-06	4.8e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—HRAS—pancreatic cancer	5.65e-06	4.77e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—KRAS—pancreatic cancer	5.65e-06	4.77e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CASP3—pancreatic cancer	5.63e-06	4.75e-05	CbGpPWpGaD
Maprotiline—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	5.59e-06	4.72e-05	CbGpPWpGaD
Maprotiline—HRH1—GPCR downstream signaling—AKT1—pancreatic cancer	5.58e-06	4.71e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	5.58e-06	4.71e-05	CbGpPWpGaD
Maprotiline—CHRM1—GPCR downstream signaling—AKT1—pancreatic cancer	5.56e-06	4.7e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—SRC—pancreatic cancer	5.56e-06	4.69e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—TP53—pancreatic cancer	5.55e-06	4.69e-05	CbGpPWpGaD
Maprotiline—CHRM3—GPCR downstream signaling—AKT1—pancreatic cancer	5.55e-06	4.68e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	5.54e-06	4.68e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CASP3—pancreatic cancer	5.53e-06	4.67e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CASP3—pancreatic cancer	5.51e-06	4.65e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CASP3—pancreatic cancer	5.5e-06	4.64e-05	CbGpPWpGaD
Maprotiline—CHRM2—GPCR downstream signaling—AKT1—pancreatic cancer	5.49e-06	4.64e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CCND1—pancreatic cancer	5.48e-06	4.63e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CASP3—pancreatic cancer	5.44e-06	4.59e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	5.43e-06	4.58e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—PIK3CA—pancreatic cancer	5.42e-06	4.57e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	5.42e-06	4.57e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	5.39e-06	4.55e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CCND1—pancreatic cancer	5.38e-06	4.54e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PPARG—pancreatic cancer	5.38e-06	4.54e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CCND1—pancreatic cancer	5.37e-06	4.53e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	5.36e-06	4.53e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	5.35e-06	4.52e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CCND1—pancreatic cancer	5.35e-06	4.51e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	5.34e-06	4.51e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—CTNNB1—pancreatic cancer	5.33e-06	4.5e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MMP9—pancreatic cancer	5.32e-06	4.49e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—CTNNB1—pancreatic cancer	5.31e-06	4.49e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—HRAS—pancreatic cancer	5.31e-06	4.48e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CCND1—pancreatic cancer	5.3e-06	4.47e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—CTNNB1—pancreatic cancer	5.3e-06	4.47e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PTEN—pancreatic cancer	5.29e-06	4.47e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—CTNNB1—pancreatic cancer	5.25e-06	4.43e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—TP53—pancreatic cancer	5.24e-06	4.42e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	5.24e-06	4.42e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—APOE—pancreatic cancer	5.23e-06	4.42e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MMP9—pancreatic cancer	5.23e-06	4.41e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MMP9—pancreatic cancer	5.21e-06	4.4e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	5.21e-06	4.39e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CD—pancreatic cancer	5.2e-06	4.39e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PTEN—pancreatic cancer	5.2e-06	4.39e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MMP9—pancreatic cancer	5.19e-06	4.38e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—PIK3CA—pancreatic cancer	5.19e-06	4.38e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PTEN—pancreatic cancer	5.18e-06	4.37e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	5.16e-06	4.36e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PTEN—pancreatic cancer	5.16e-06	4.36e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MMP9—pancreatic cancer	5.14e-06	4.34e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PTEN—pancreatic cancer	5.11e-06	4.32e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	5.08e-06	4.29e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling by GPCR—AKT1—pancreatic cancer	5.07e-06	4.28e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling by GPCR—AKT1—pancreatic cancer	5.05e-06	4.26e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling by GPCR—AKT1—pancreatic cancer	5.04e-06	4.25e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—TP53—pancreatic cancer	5.02e-06	4.24e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—HRAS—pancreatic cancer	5.01e-06	4.23e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling by GPCR—AKT1—pancreatic cancer	4.99e-06	4.21e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—MYC—pancreatic cancer	4.98e-06	4.21e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	4.97e-06	4.2e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.95e-06	4.18e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—SRC—pancreatic cancer	4.91e-06	4.14e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	4.9e-06	4.14e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	4.87e-06	4.11e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—SRC—pancreatic cancer	4.83e-06	4.08e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—SRC—pancreatic cancer	4.82e-06	4.07e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—SRC—pancreatic cancer	4.8e-06	4.05e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—HRAS—pancreatic cancer	4.8e-06	4.05e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—SRC—pancreatic cancer	4.79e-06	4.04e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	4.78e-06	4.03e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—SRC—pancreatic cancer	4.74e-06	4e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—STAT3—pancreatic cancer	4.73e-06	3.99e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	4.72e-06	3.99e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—NRAS—pancreatic cancer	4.72e-06	3.98e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	4.7e-06	3.97e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—VEGFA—pancreatic cancer	4.69e-06	3.96e-05	CbGpPWpGaD
Maprotiline—HTR7—Signaling Pathways—AKT1—pancreatic cancer	4.69e-06	3.96e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—VEGFA—pancreatic cancer	4.68e-06	3.95e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—VEGFA—pancreatic cancer	4.66e-06	3.94e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	4.66e-06	3.93e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—STAT3—pancreatic cancer	4.65e-06	3.92e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	4.65e-06	3.92e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—NRAS—pancreatic cancer	4.64e-06	3.91e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—STAT3—pancreatic cancer	4.63e-06	3.91e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—NRAS—pancreatic cancer	4.62e-06	3.9e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—VEGFA—pancreatic cancer	4.62e-06	3.9e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—STAT3—pancreatic cancer	4.62e-06	3.9e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—NRAS—pancreatic cancer	4.61e-06	3.89e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	4.6e-06	3.89e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—STAT3—pancreatic cancer	4.57e-06	3.86e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—NRAS—pancreatic cancer	4.56e-06	3.85e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PPARG—pancreatic cancer	4.56e-06	3.85e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CB—pancreatic cancer	4.53e-06	3.83e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PTGS2—pancreatic cancer	4.49e-06	3.79e-05	CbGpPWpGaD
Maprotiline—CHRM4—Signaling Pathways—AKT1—pancreatic cancer	4.43e-06	3.74e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—MYC—pancreatic cancer	4.4e-06	3.71e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	4.39e-06	3.7e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—PIK3CA—pancreatic cancer	4.36e-06	3.68e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—MYC—pancreatic cancer	4.33e-06	3.65e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—MYC—pancreatic cancer	4.32e-06	3.64e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	4.32e-06	3.64e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TGFB1—pancreatic cancer	4.31e-06	3.64e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—MYC—pancreatic cancer	4.3e-06	3.63e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—EGFR—pancreatic cancer	4.3e-06	3.63e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TGFB1—pancreatic cancer	4.29e-06	3.62e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—MYC—pancreatic cancer	4.29e-06	3.62e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TGFB1—pancreatic cancer	4.28e-06	3.61e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	4.27e-06	3.61e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—MYC—pancreatic cancer	4.25e-06	3.59e-05	CbGpPWpGaD
Maprotiline—CHRM5—Signaling Pathways—AKT1—pancreatic cancer	4.24e-06	3.58e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TGFB1—pancreatic cancer	4.24e-06	3.58e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PTGS2—pancreatic cancer	4.23e-06	3.57e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	4.23e-06	3.57e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	4.23e-06	3.57e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—EGFR—pancreatic cancer	4.22e-06	3.56e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—EGFR—pancreatic cancer	4.21e-06	3.55e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—EGFR—pancreatic cancer	4.2e-06	3.54e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—EGFR—pancreatic cancer	4.16e-06	3.51e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	4.15e-06	3.5e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—TP53—pancreatic cancer	4.09e-06	3.45e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—KRAS—pancreatic cancer	4.06e-06	3.43e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	4e-06	3.37e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—KRAS—pancreatic cancer	3.99e-06	3.37e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—KRAS—pancreatic cancer	3.98e-06	3.36e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—KRAS—pancreatic cancer	3.96e-06	3.35e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—KRAS—pancreatic cancer	3.93e-06	3.31e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PTEN—pancreatic cancer	3.92e-06	3.31e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	3.91e-06	3.3e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	3.73e-06	3.15e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PTEN—pancreatic cancer	3.69e-06	3.12e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	3.67e-06	3.1e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—PIK3CA—pancreatic cancer	3.67e-06	3.09e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—PIK3CA—pancreatic cancer	3.65e-06	3.08e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—PIK3CA—pancreatic cancer	3.64e-06	3.07e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	3.62e-06	3.05e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—TP53—pancreatic cancer	3.61e-06	3.05e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—PIK3CA—pancreatic cancer	3.61e-06	3.04e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PTGS2—pancreatic cancer	3.59e-06	3.03e-05	CbGpPWpGaD
Maprotiline—CHRM3—Metabolism—AKT1—pancreatic cancer	3.56e-06	3e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—TP53—pancreatic cancer	3.55e-06	3e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—TP53—pancreatic cancer	3.55e-06	2.99e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—TP53—pancreatic cancer	3.53e-06	2.98e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—TP53—pancreatic cancer	3.52e-06	2.97e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—TP53—pancreatic cancer	3.49e-06	2.94e-05	CbGpPWpGaD
Maprotiline—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	3.46e-06	2.92e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—HRAS—pancreatic cancer	3.45e-06	2.92e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	3.4e-06	2.87e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—HRAS—pancreatic cancer	3.39e-06	2.86e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—HRAS—pancreatic cancer	3.38e-06	2.85e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—HRAS—pancreatic cancer	3.37e-06	2.84e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—HRAS—pancreatic cancer	3.34e-06	2.82e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PTEN—pancreatic cancer	3.13e-06	2.64e-05	CbGpPWpGaD
Maprotiline—DRD2—Signaling Pathways—AKT1—pancreatic cancer	3.05e-06	2.57e-05	CbGpPWpGaD
Maprotiline—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	3e-06	2.53e-05	CbGpPWpGaD
Maprotiline—HRH1—Signaling Pathways—AKT1—pancreatic cancer	2.99e-06	2.53e-05	CbGpPWpGaD
Maprotiline—CHRM1—Signaling Pathways—AKT1—pancreatic cancer	2.98e-06	2.52e-05	CbGpPWpGaD
Maprotiline—CHRM3—Signaling Pathways—AKT1—pancreatic cancer	2.98e-06	2.51e-05	CbGpPWpGaD
Maprotiline—CHRM2—Signaling Pathways—AKT1—pancreatic cancer	2.95e-06	2.49e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—PIK3CA—pancreatic cancer	2.76e-06	2.33e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	2.6e-06	2.2e-05	CbGpPWpGaD
Maprotiline—ABCB1—Metabolism—AKT1—pancreatic cancer	2.26e-06	1.91e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	2.21e-06	1.86e-05	CbGpPWpGaD
Maprotiline—CYP2D6—Metabolism—AKT1—pancreatic cancer	2.13e-06	1.8e-05	CbGpPWpGaD
Maprotiline—CYP1A2—Metabolism—AKT1—pancreatic cancer	1.8e-06	1.52e-05	CbGpPWpGaD
